TransCode Therapeutics Inc.
RNAZ | NASDAQ
$1.76
+$0.11 (+6.67%)
At close: Sep 21, 2026, 4:00 PM ET
$1.84
+$0.08 (+4.55%)
After-hours:
Sep 21, 2026, 7:30 PM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | 534.86K | 516.75K | 98.61K | 42.47K | n/a |
Gross Profit | n/a | -534.86K | -516.75K | -98.61K | -42.47K | n/a |
Operating Income | -27.98M | -15.66M | -19.42M | -18.67M | -6.15M | -726.6K |
Interest Income | 79.2K | 684 | 5.29K | 20.41K | 664 | 136 |
Pretax Income | -34.44M | -16.75M | -18.55M | -17.56M | -6.84M | -2.34M |
Net Income | -34.66M | -16.75M | -18.55M | -17.56M | -6.84M | -2.34M |
Selling & General & Admin | 5.77M | 5.51M | 6.64M | 8.33M | 3.35M | 442.15K |
Research & Development | 13.42M | 9.62M | 12.26M | 10.23M | 2.75M | 284.46K |
Other Expenses | 8.79M | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 27.98M | 15.13M | 18.9M | 18.57M | 6.11M | 726.6K |
Interest Expense | 6.62K | 26.81K | 55.9K | 17.56M | 95.07K | 394.57K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 27.98M | 15.66M | 19.42M | 18.67M | 6.15M | 726.6K |
Income Tax Expense | 226.07K | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 689.71K | 356.12K | 5.42K | 16.22K | 10.53K | 7.98K |
Shares Outstanding (Diluted) | 689.71K | 356.12K | 5.42K | 16.22K | 10.53K | 7.98K |
EPS (Basic) | -52.59 | -47.14 | -3.45K | -73.19K | -648 | -293.76 |
EPS (Diluted) | -52.59 | -47.14 | -3.45K | -1.08K | -648 | -293.76 |
EBITDA | -34.31M | -16.19M | -17.97M | -17.47M | -6.71M | -1.95M |
EBIT | -34.43M | -16.73M | -18.49M | -17.56M | -6.75M | -1.95M |
Depreciation & Amortization | 114.18K | 534.86K | 516.75K | 98.61K | 42.47K | n/a |
Add to Watchlist
Select watchlists to add or remove RNAZ